Skip to main content
ChemistryOpen logoLink to ChemistryOpen
. 2020 Jan 29;9(1):93–96. doi: 10.1002/open.201900343

Asymmetric Synthesis of 4,4‐(Difluoro)glutamic Acid via Chiral Ni(II)‐Complexes of Dehydroalanine Schiff Bases. Effect of the Chiral Ligands Structure on the Stereochemical Outcome

Yoshinori Tokairin 1,, Yuhei Shigeno 3, Jianlin Han 2,, Gerd‐Volker Röschenthaler 1,, Hiroyuki Konno 3, Hiroki Moriwaki 4, Vadim A Soloshonok 5,6
PMCID: PMC6988766  PMID: 32015956

Abstract

Four differently substituted chiral Ni(II)‐complexes of dehydroalanine Schiff base were prepared and reacted with BrCF2COOEt/Cu under the standard reaction conditions. The observed diastereoselectivity was found to depend on the degree and pattern of chlorine substitution for hydrogen in the structure of the dehydroalanine complexes. The unsubstituted complex gave the ratio of diastereomers (S)(2S)/(S)(2R) of 66/34. On the other hand, introduction of chlorine atoms in the strategic positions on the chiral ligands allowed to achieve a practically attractive diastereoselectivity of (∼98.5/1.5). Diastereomerically pure major product was disassembled to prepare 9‐fluorenylmethyloxycarbonyl (Fmoc) derivative of (S)‐4,4‐difluoroglutamic acid.

Keywords: asymmetric synthesis, tailor-made amino acids, fluorine, Schiff bases, Ni(II)-complexes


The secret is in the structure! An asymmetric Cu‐promoted Michael addition reaction between chiral Schiff base Ni(II)‐complexes and BrCF2COOEt is developed providing an easy method for the synthesis of (S)‐4,4‐difluoroglutamic acid.

graphic file with name OPEN-9-93-g005.jpg


Though pharmaceutical molecules span a wide range of structures, two major common traits emerge upon analysis. One of them is ever increasing number of medicinal compounds containing fluorine.1 In fact, fluorine editing or fluorine scan is currently a well‐established platform in new drug development2 allowing for high degree of rational control over physicochemical and biological properties.3 The second trend is biological application of tailor‐made amino acids (AAs)4 as structural scaffolds to mimic 3D structure of targeted receptors.5 The growing acceptance of peptides and modified peptides as drugs,6 indicates that the role of tailor‐made AAs in the drug design will continue to grow. In line with these key structural features, fluorine‐containing amino acids are in high demand in nearly every sector of medicinal chemistry and drug design.7 Chemistry of fluoro‐AAs and their derivatives is comprehensively covered in monograph8 and more recent review articles.9, 10 Our long‐standing interest in tailor‐made AAs, focuses mostly on fluorinated α‐11 and β‐AAs‐,12 but also includes phosphorus‐containing13 and conformationally constrained derivatives14 as well as their not‐linear chiroptical properties, such self‐disproportionation of enantiomers.15 Methodologically, along with other research groups, we are developing chemistry of Ni(II) complexes of AA Schiff bases (Scheme 1), derived from chiral tridentate ligands, as a general approach for asymmetric synthesis of various tailor‐made AAs.9i, 16

Scheme 1.

Scheme 1

Asymmetric homologation of chiral glycine (S)‐1 and dehydroalanine (S)‐4 Schiff bases.

In particular, Ni(II) complexes of glycine Schiff base 1, derived from (S)‐ or (R)‐proline‐containing ligands, can be conventionally transformed to the derivatives of higher AAs via alkyl halide alkylation,17 aldol,18 Mannich,19 Michael20 addition reactions, as well as various multi‐step transformations.21 Homologation products 2 are conveniently disassembled under acidic conditions to afford the target AAs 3 along with recovery and reuse of the corresponding chiral ligands. By contrast, the homologation of dehydroalanine Schiff bases complexes (S)‐4 is a significantly less studied area of this chemistry. Thus, only a handful of examples16, 22 of additions to (S)‐4, limited mostly to NH and OH nucleophiles, have been reported so far. One may agree that reactions of dehydroalanine complexes (S)‐4, via intermediates 5, would allow preparation of structural types of AAs unavailable by homologation of glycine derivatives (S)‐1. However, the reactivity and synthetic potential of chiral equivalents of electrophilic dehydroalanine (S)‐4 remains virtually unexplored. Recently we reported the reactions of achiral Ni(II) complexes of dehydroalanin 7 23 with BrCF2COOEt providing direct access to 4,4‐(difluoro)glutamic acid 9 24 via intermediate 8. Besides the synthetic value, the previous work23 has demonstrated that Cu(II) species are compatible with Ni(II)‐chelated starting materials and the dehydroalanine Schiff bases are sufficiently electrophilic to react with BrCuCF2COOEt. In the present work we extend these findings to the series of chiral dehydroalanine equivalents (S)‐4 and evaluate the level of stereochemical outcome as a function of dehydroalanine complexes structure. Furthermore, we describe a convenient procedure for asymmetric synthesis of preparation of N‐Fmoc‐4,4‐(difluoro)glutamic acid, a valuable building block in medicinal chemistry and drug design.24, 25

Syntheses of the requisite tridentate chiral ligands26 and glycine Schiff base complexes 10 ad 27 was performed according to the literature procedures (Scheme 2). The transformation of the glycine moiety in 10a‐d to dehydroalanine residue of 12 a–d was accomplished by two‐step procedure by analogy with the literature data22 and the method used in the previous work.23 Starting glycine complexes 10 a–d were treated with formaldehyde in the presence of triethylamine to furnish intermediate serine containing compounds 11 a–d. Dehydration of 11 a–d to 12 a–d takes place via in situ formation the corresponding esters followed by the elimination of acetic acid in acetonitrile under reflux. Dehydroalanine complexes 12 a 22a and 12 c 22e are known compounds, while derivatives 12 b and 12 d have not been previously described.

Scheme 2.

Scheme 2

Two‐step synthesis of known (S)‐12 a,c and new (S)‐12 b,d dehydroalanine Schiff base Ni(II) complexes from glycine derivatives (S)‐10 ad.

Our interest in studying the reaction of four different dehydroalanine complexes 12 a–d stems from the reports28 that in the case of glycine complexes 10, a seemingly insignificant structural modifications with chlorine atoms or other halogen or alkyl substituents, results in a noticeable differences in the stereochemical outcome of their reactions with various electrophiles. In particular, it was shown29 that 10 d provides for the most optimal parallel displaced type of aromatic interactions between o‐amino‐benzophenone and Pro N‐benzyl rings controlling the stereochemical outcome.30 Consequently, it was rather important to investigate whether or not this trend would hold true for the new platform of dehydroalanine Schiff base complexes in the reactions with nucleophiles.

As presented in Scheme 3, the reactions of complexes 12 ad with BrCF2COOEt was conducted in the presence of activated Cu powder in acetonitrile. The progress of the additions was monitored by TLC.

Scheme 3.

Scheme 3

Reactions of dehydroalanine Schiff base Ni(II) complexes (S)‐12 ad with BrCF2COOEt/Cu.

The reaction conditions were optimized using dehydroalanine complex (S)‐12 d allowing to define the following settings: 6 equivalents of the activated Cu powder, 3 equivalents of bromodifluoroacetate, 0.9 equivalents of tetramethylene ethylendiamine (TMEDA) in acetonitrile at 70 °C. Under these conditions, the reactions proceeded quite rapidly, being virtually completed in about 20 min of the reaction time. The additions of BrCF2COOEt/Cu with a series of dehydroalanine complexes (S)‐12 ad were conducted under the same conditions to assess the relationships between the complexes’ structure and the level of the stereochemical outcome. The results reported in Scheme 3 were absolutely exciting as the levels of the asymmetric induction clearly correlated with the degree and pattern of chlorine substitution for hydrogen in the structure of complexes (S)‐12 ad. Thus, unsubstituted dehydroalanine complex gave the ratio of diastereomers (S)(2S)‐13 a/(S)(2R)‐14 a of 66/34. Introduction of a chlorine atom in the p‐position of the o‐amino‐benzophenone moiety allowed to increase the diastereomeric ratio to 80/20. On the other hand, the presence of two chlorine atoms in the p‐ and m‐position of the N‐benzyl moiety was found to be more effective in controlling the stereochemical outcome increasing the ratio of (S)(2S)‐13 c/(S)(2R)‐14 c to 90/10. Finally, the chlorination of both of the o‐amino‐benzophenone and N‐benzyl moieties gave the best result affording diastereomers (S)(2S)‐13 d and (S)(2R)‐14 d with practically attractive diastereoselectivity of >98/2 (∼98.5/1.5).

Considering the above mentioned work,29, 30 these results, while quite spectacular, were not entirely unexpected. In particular, the superior stereocontrolling properties of the tri‐chloro derivatives of glycine complexes (S)‐ or (R)‐1 (Scheme 1) have been convincingly demonstrated.28, 30 The trend of the stereocontrolling properties observed in the present work is likely suggesting that the previously determined aromatic interactions between the o‐amino‐benzophenone and the N‐benzyl rings are of greater general importance Nevertheless, the direct comparison of all four differently substituted derivatives have never been conducted before emphasizing the methodological importance of the results obtained.

As a final synthetic step in this work, we performed disassembly of Ni(II) complex (S)(2R)‐13 d as presented in Scheme 4.

Scheme 4.

Scheme 4

Disassembly of major diastereomer (S)‐13 d, recycling of chiral ligand (S)‐15 and preparation of Fmoc‐derivative (S)‐17.

Major diastereomer (S)(2S)‐13 d, obtained as described in Scheme 3, was additionally purified by column chromatography to remove the residual amounts of minor product (S)(2R)‐14 d. Diastereomerically pure (S)(2S)‐13 d was subjected to the action of 6 N HCl in THF (1 : 5) at at ambient temperature. The red‐colored mixture gradually changed to a green solution indication the disassembly of the starting (S)(2S)‐13 d complex and formation of NiCl2. The precipitate of chiral ligand (S)‐15 was removed by filtration and the solution was concentrated and treated with EDTA to chelate the Ni(II) ions. The protection of the in situ formed hydrochloric salt of (S)‐16 was performed using Fmoc‐OSu in dioxane at ambient temperature in the presence of K2CO3.

In summary, four differently substituted chiral Ni(II)‐complexes of dehydroalanine Schiff base were prepared and their addition reactions with BrCF2COOEt/Cu were studied under the standard reaction conditions. The observed diastereoselectivity rather remarkably was found to depend on the degree and pattern of chlorine substitution for hydrogen in the structure of the starting dehydroalanine complexes. While the unsubstituted complex gave the ratio of diastereomers (S)(2S)‐13 a/(S)(2R)‐14 a of 66/34, introduction of chlorine atoms in the p‐position of the o‐amino‐benzophenone and the p‐ and m‐positions of the N‐benzyl moieties led to gradual increase of the stereochemical outcome allowing to achieve a synthetically attractive value of >98/2 diastereomeric ration. These results clearly suggest the similarity between chiral Ni(II) complexes of dehydroalanine and glycine in the nature of the stereocontrol being governed by the parallel displaced type of aromatic interactions between o‐amino‐benzophenone and Pro N‐benzyl rings. Preparation of Fmoc derivative of (S)‐4,4‐difluoroglutamic acid by disassembling of the major diastereomer was successfully performed.

Supporting information

As a service to our authors and readers, this journal provides supporting information supplied by the authors. Such materials are peer reviewed and may be re‐organized for online delivery, but are not copy‐edited or typeset. Technical support issues arising from supporting information (other than missing files) should be addressed to the authors.

Supplementary

Acknowledgements

This work was supported in part by German Research Foundation (Grant RO 362/80‐1). We gratefully acknowledge the financial support from the Ikerbasque, the Basque Foundation for Science.

Y. Tokairin, Y. Shigeno, J. Han, G.-V. Röschenthaler, H. Konno, H. Moriwaki, V. A. Soloshonok, ChemistryOpen 2020, 9, 93.

Contributor Information

Dr. Yoshinori Tokairin, Email: naganau@gmail.com.

Dr. Jianlin Han, Email: hanjl@njfu.edu.cn.

Prof. Dr. Gerd‐Volker Röschenthaler, Email: g.roeschenthaler@jacobs-university.de.

References

  • 1. 
  • 1a. Zhou Y., Wang J., Gu Z., Wang S., Zhu W., Aceña J. L., Soloshonok V. A., Izawa K., Liu H., Chem. Rev. 2016, 116, 422–518; [DOI] [PubMed] [Google Scholar]
  • 1b. Zhu W., Wang J., Wang S., Gu Z., Aceña J. L., Izawa K., Liu H., Soloshonok V. A., J. Fluorine Chem. 2014, 167, 37–54; [Google Scholar]
  • 1c. Mei H., Han J., Fustero S., Medio-Simon M., Sedgwick D. M., Santi C., Ruzziconi R., Soloshonok V. A., Chem. Eur. J. 2019, 25, 11797–11819. [DOI] [PubMed] [Google Scholar]
  • 2. 
  • 2a. Wang J., Sánchez-Roselló M., Aceña J. L., del Pozo C., Sorochinsky A. E., Fustero S., Soloshonok V. A., Liu H., Chem. Rev. 2014, 114, 2432–2506; [DOI] [PubMed] [Google Scholar]
  • 2b. Meanwell N. A., J. Med. Chem. 2018, 61, 5822–5880; [DOI] [PubMed] [Google Scholar]
  • 2c. Ilardi E. A., Vitaku E., Njardarson J. T., J. Med. Chem. 2014, 57, 2832–2842. [DOI] [PubMed] [Google Scholar]
  • 3. Zhu Y., Han J. L., Wang J., Shibata N., Sodeoka M., Soloshonok V. A., Coelho J. A. S., Toste F. D., Chem. Rev. 2018. , 118, 3887–3964. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.For the definition of “tailor-made amino acids”, see: Soloshonok V. A., Cai C., Hruby V. J., Meervelt L. V., Tetrahedron 1999, 55, 12045–12058. [Google Scholar]
  • 5. 
  • 5a.Asymmetric Synthesis and Application of alpha-Amino Acids; V. A. Soloshonok, K. Izawa, Eds.; ACS Symposium Series 1009; Oxford University Press, 2009;
  • 5b. Henninot A., Collins J. C., Nuss J. M., J. Med. Chem. 2018, 61, 1382–1414; [DOI] [PubMed] [Google Scholar]
  • 5c. Blaskovich M. A. T., J. Med. Chem. 2016, 59, 10807–10836; [DOI] [PubMed] [Google Scholar]
  • 5d. Soloshonok V. A., Sorochinsky A. E., Synthesis 2010, 2319–2344. [Google Scholar]
  • 6. 
  • 6a. Ma J. S., Chim. Oggi-Chem. Today 2003, 21, 65–68; [Google Scholar]
  • 6b. Hodgson D. R. W., Sanderson J. M., Chem. Soc. Rev. 2004, 33, 422–430; [DOI] [PubMed] [Google Scholar]
  • 6c. Sato T., Izawa K., Aceña J. L., Liu H., Soloshonok V. A., Eur. J. Org. Chem. 2016, 2757–2774; [Google Scholar]
  • 6d. Wang S., Wang Y., Wang J., Sato T., Izawa K., Soloshonok V. A., Liu H., Curr. Pharm. Des. 2017, 23, 4493–4554. [DOI] [PubMed] [Google Scholar]
  • 7. Mei H., Han J., Klika K. D., Izawa K., Sato T., Meanwell N. A., Soloshonok V. A., Eur. J. Med. Chem. 2020, 186, 111826. [DOI] [PubMed] [Google Scholar]
  • 8.Fluorine-Containing Amino Acids. Synthesis and Properties; V. P. Kukhar, V. A. Soloshonok, Eds.; John Wiley & Sons Ltd., 1994.
  • 9.For recent Reviews on fluorinated a-AAs, see:
  • 9a. Smits R., Cadicamo C. D., Burger K., Koksch B., Chem. Soc. Rev. 2008, 37, 1727–1739; [DOI] [PubMed] [Google Scholar]
  • 9b. Kukhar V. P., Sorochinsky A. E., Soloshonok V. A., Future Med. Chem. 2009, 1, 793–819; [DOI] [PubMed] [Google Scholar]
  • 9c. Sorochinsky A. E., Soloshonok V. A., J. Fluorine Chem. 2010, 131, 127–139; [Google Scholar]
  • 9d. Tarui A., Sato K., Omote M., Kumadaki I., Ando A., Adv. Synth. Catal. 2010, 352, 2733–2744; [Google Scholar]
  • 9e. Czekelius C., Tzschucke C. C., Synthesis 2010, 543–566; [Google Scholar]
  • 9f. Qiu X.-L., Qing F.-L., Eur. J. Org. Chem. 2011, 3261–3278; [Google Scholar]
  • 9g. Turcheniuk K. V., Kukhar V. P., Roeschenthaler G.-V., Luis Acena J., Soloshonok V. A., Sorochinsky A. E., RSC Adv. 2013, 3, 6693–6716; [Google Scholar]
  • 9h. Aceña J. L., Sorochinsky A. E., Soloshonok V. A., Synthesis 2012, 44, 1591–1602; [Google Scholar]
  • 9i. Aceña J. L., Sorochinsky A. E., Moriwaki H., Sato T., Soloshonok V. A., J. Fluorine Chem. 2013, 155, 21–38. [Google Scholar]
  • 10.For recent reviews on fluorinated β-AAs, see:
  • 10a. Mikami K., Fustero S., Sánchez-Roselló M., Aceña J. L., Soloshonok V. A., Sorochinsky A. E., Synthesis 2011, 3045–3079; [Google Scholar]
  • 10b. Han J., Sorochinsky A. E., Ono T., Soloshonok V. A., Curr. Org. Synth. 2011, 8, 281–294; [Google Scholar]
  • 10c. Aceña J. L., Simon-Fuentes A., Santos F., Curr. Org. Chem. 2010, 14, 928–949. [Google Scholar]
  • 11. 
  • 11a. Soloshonok V. A., Gerus I. I., Yagupolskii Y. L., Kukhar V. P., Zh. Org. Khim. 1987, 23, 2308–2313; [Google Scholar]
  • 11b. Bravo P., Capelli S., Meille S. V., Viani F., Zanda M., Kukhar V. P., Soloshonok V. A., Tetrahedron: Asymmetry 1994, 5, 2009–2018; [Google Scholar]
  • 11c. Sorochinsky A. E., Ueki H., Aceña J. L., Ellis T. K., Moriwaki H., Sato T., Soloshonok V. A., J. Fluorine Chem. 2013, 152, 114–118. [Google Scholar]
  • 12. 
  • 12a. Soloshonok V. A., Kukhar V. P., Tetrahedron 1996, 52, 6953–6964; [Google Scholar]
  • 12b. Soloshonok V. A., Ono T., Soloshonok I. V., J. Org. Chem. 1997, 62, 7538–7539; [Google Scholar]
  • 12c. Shibata N., Nishimine T., Shibata N., Tokunaga E., Kawada K., Kagawa T., Sorochinsky A. E., Soloshonok V. A., Chem. Commun. 2012, 48, 4124–4126. [DOI] [PubMed] [Google Scholar]
  • 13. 
  • 13a. Turcheniuk K. V., Poliashko K. O., Kukhar V. P., Rozhenko A. B., Soloshonok V. A., Sorochinsky A. E., Chem. Commun. 2012, 48, 11519–11521; [DOI] [PubMed] [Google Scholar]
  • 13b. Röschenthaler G.-V., Kukhar V. P., Kulik I. B., Belik M. Y., Sorochinsky A. E., Rusanov E. B., Soloshonok V. A., Tetrahedron Lett. 2012, 53, 539–542; [Google Scholar]
  • 13c. Röschenthaler G.-V., Kukhar V. P., Kulik I. B., Sorochinsky A. E., Soloshonok V. A., J. Fluorine Chem. 2011, 132, 834–837. [Google Scholar]
  • 14. 
  • 14a. Qiu W., Gu X., Soloshonok V. A., Carducci M. D., Hruby V. J., Tetrahedron Lett. 2001, 42, 145–148; [Google Scholar]
  • 14b. Ellis T. K., Hochla V. M., Soloshonok V. A., J. Org. Chem. 2003, 68, 4973–4976; [DOI] [PubMed] [Google Scholar]
  • 14c. Yamada T., Okada T., Sakaguchi K., Ohfune Y., Ueki H., Soloshonok V. A., Org. Lett. 2006, 8, 5625–5628. [DOI] [PubMed] [Google Scholar]
  • 15. 
  • 15a. Han J., Wzorek A., Kwiatkowska M., Soloshonok V. A., Klika K. D., Amino Acids 2019, 51, 865–889; [DOI] [PubMed] [Google Scholar]
  • 15b. Sorochinsky A. E., Aceña J. L., Soloshonok V. A., Synthesis 2013, 45, 141–152; [Google Scholar]
  • 15c. Han J., Nelson D. J., Sorochinsky A. E., Soloshonok V. A., Curr. Org. Synth. 2011, 8, 310–317. [Google Scholar]
  • 16.For reviews covering chemistry and applications of Ni(II) complexes of AAs, see:
  • 16a. Aceña J. L., Sorochinsky A. E., Soloshonok V., Amino Acids 2014, 46, 2047–2073; [DOI] [PubMed] [Google Scholar]
  • 16b. Wang Y., Song X., Wang J., Moriwaki H., Soloshonok V. A., Liu H., Amino Acids 2017, 49, 1487–1520. [DOI] [PubMed] [Google Scholar]
  • 17. Ellis T. K., Martin C. H., Tsai C. M., Ueki H., Soloshonok V. A., J. Org. Chem. 2003, 68, 6208–6214. [DOI] [PubMed] [Google Scholar]
  • 18. Soloshonok V. A., Kukhar V. P., Galushko S. V., Svistunova N. Y., Avilov D. V., Kuzmina N. A., Raevski N. I., Struchkov Y. T., Pisarevsky A. P., Belokon Y. N., J. Chem. Soc. Perkin Trans. 1 1993, 3143–3155. [Google Scholar]
  • 19. Kawamura A., Moriwaki H., Röschenthaler G.-V., Kawada K., Aceña J. L., Soloshonok V. A., J. Fluorine Chem. 2015, 171, 67–72. [Google Scholar]
  • 20. Soloshonok V. A., Cai C., Hruby V. J., Org. Lett. 2000, 2, 747–750. [DOI] [PubMed] [Google Scholar]
  • 21. Yamada T., Sakaguchi K., Shinada T., Ohfune Y., Soloshonok V. A., Tetrahedron: Asymmetry. 2008, 19, 2789–2795. [Google Scholar]
  • 22. 
  • 22a. Saghiyan A. S., Geolchanyan A. V., Synth. Commun. 2006, 36, 3667–3677; [Google Scholar]
  • 22b. Saghiyan A. S., Geolchanyan A. V., Petrosyan S. G., Ghochikyan T. V., Haroutunyan V. S., Avetisyan A. A., Belokon Y. N., Fisher K., Tetrahedron: Asymmetry 2004, 15, 705–711; [Google Scholar]
  • 22c. Saghiyan A. S., Hambardzumyan H. H., Manasyan L. L., Petrosyan A. A., Maleev V. I., Peregudov A. S., Synth. Commun. 2005, 35, 449–459; [Google Scholar]
  • 22d. Saghiyan A. S., Manasyan L. L., Geolchanyan A. V., Hovhannisyan A. M., Ghochikyan T. V., Haroutunyan V. S., Avetisyan A. A., Mirzoyan K. S., Maleev V. I., Khrustalev V. N., Tetrahedron: Asymmetry 2006, 17, 2743–2753; [Google Scholar]
  • 22e. Saghiyan A. S., Stepanyan L. A., Manasyan L. L., Geolchanyan A. V., Djamgaryan S. M., Ajvazyan H. R., Panosyan H. A., Maleev V. I., Saveleva T. F., Tetrahedron: Asymmetry 2010, 21, 2638–2645; [Google Scholar]
  • 22f. Saghiyan A. S., Simonyan H. M., Stepanyan L. A., Ghazaryan S. G., Geolchanyan A. V., Manasyan L. L., Ghochikyan V. T., Ghochikyan T. V., Hovhannisyan N. A., Gevorgyan A., Iaroshenko V. O., P. Tetrahedron: Asymmetry 2012, 23, 891–897; [Google Scholar]
  • 22g. Saghiyan A. S., Mkrtchyan G. M., Dadayan A. S., Petrosyan S. G., Geolchanyan A. V., Simonyan H. M., Mkrtchyan A. F., Mkrtchyan S., Gevorgyan A., Iaroshenko V. O., Langer P., Tetrahedron: Asymmetry 2013, 24, 229–232; [Google Scholar]
  • 22h. Taylor S. M., Yamada T., Ueki H., Soloshonok V. A., Tetrahedron Lett. 2004, 45, 9159–9162; [Google Scholar]
  • 22i. Soloshonok V. A., Yamada T., Ueki H., Moore A. M., Cook T. K., Arbogast K. L., Soloshonok A. V., Martin C. H., Ohfune Y., Tetrahedron 2006, 62, 6412–6419. [Google Scholar]
  • 23. Tokairin Y., Soloshonok V. A., Konno H., Moriwaki H., Röschenthaler G.-V., J. Fluorine Chem. 2019, 227, 109376. [Google Scholar]
  • 24. 
  • 24a. Kitagawa O., Hashimoto A., Kobayashi Y., Taguchi T., Chem. Lett. 1990, 1307–1310; [Google Scholar]
  • 24b. Yajima T., Yamaguchi K., Hirokane R., Nogami E., J. Fluorine Chem. 2013, 150, 1–7; [Google Scholar]
  • 24c. Hugenberg V., Haufe G., J. Fluorine Chem. 2012, 143, 238–262; [Google Scholar]
  • 24d. Konas D. W., Coward J. K., Org. Lett. 1999, 1, 2105–2107; [DOI] [PubMed] [Google Scholar]
  • 24e. Ulbrich D., Daniliuc C. G., Haufe G., J. Fluorine Chem. 2016, 188, 65–75; [Google Scholar]
  • 24f. Kondratov I. S., Bugera M. Y., Tolmachova N. A., Daniliuc C. G., Haufe G., J. Fluorine Chem. 2018, 211, 100–108; [Google Scholar]
  • 24g. Sato K., Omote M., Ando A., Kumadaki I., J. Fluorine Chem. 2004, 125, 509–515; [Google Scholar]
  • 24h. Sato K., Nakazato S., Enko H., Tsujita H., Fujita K., Yamamoto T., Omote M., Ando A., Kumadaki I., J. Fluorine Chem. 2003, 121, 105–107; [Google Scholar]
  • 24i. Sato K., Tamura M., Tamoto K., Omote M., Ando A., Kumadaki I., Chem. Pharm. Bull. 2000, 48, 1023–1025. [DOI] [PubMed] [Google Scholar]
  • 25. 
  • 25a. Konas D. W., Pankuch J. J., Coward J., Synthesis 2002, 2616–2626; [Google Scholar]
  • 25b. Meffre P., Dave R., Leroy J., Badet B., Tetrahedron Lett. 2001, 42, 8625–8627. [Google Scholar]
  • 26. Romoff T. T., Palmer A. B., Mansour N., Creighton C. J., Miwa T., Ejima Y., Moriwaki H., Soloshonok V. A., Org. Process Res. Dev. 2017. , 21, 732–739. [Google Scholar]
  • 27. 
  • 27a. Ueki H., Ellis T. K., Martin C. H., Soloshonok V. A., Eur. J. Org. Chem. 2003, 1954–1957; [DOI] [PubMed] [Google Scholar]
  • 27b. Ueki H., Ellis T. K., Martin C. H., Bolene S. B., Boettiger T. U., Soloshonok V. A., J. Org. Chem. 2003, 68, 7104–7107. [DOI] [PubMed] [Google Scholar]
  • 28. 
  • 28a. Nian Y., Wang J., Zhou S., Wang S., Moriwaki H., Kawashima A., Soloshonok V. A., Liu H., Angew. Chem. Int. Ed. 2015, 54, 12918–12922; [DOI] [PubMed] [Google Scholar]; Angew. Chem. 2015, 127, 13110–13114; [Google Scholar]
  • 28b. Nian Y., Wang J., Zhou S., Dai W., Wang S., Moriwaki H., Kawashima A., Soloshonok V. A., Liu H., Org J., Chem. 2016, 81, 3501–3508; [DOI] [PubMed] [Google Scholar]
  • 28c. Takeda R., Abe H., Shibata N., Moriwaki H., Izawa K., Soloshonok V. A., Org. Biomol. Chem. 2017, 15, 6978–6983; [DOI] [PubMed] [Google Scholar]
  • 28d. Yamamoto J., Kawashima A., Kawamura A., Abe H., Moriwaki H., Shibata N., Soloshonok V. A., Eur. J. Org. Chem. 2017, 1931–1939. [Google Scholar]
  • 29. Nian Y., Wang J., Moriwaki H., Soloshonok V. A., Liu H., Dalton Trans. 2017, 46, 4191–4198. [DOI] [PubMed] [Google Scholar]
  • 30.For most recent applications of glycine complex 10 d for large-scale synthesis of fluorinated amino acids, see:
  • 30a. Mei H., Han J., Takeda R., Sakamoto T., Miwa T., Minamitsuji Y., Moriwaki H., Abe H., Soloshonok V. A., ACS Omega 2019, 4, 11844–11851; [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30b. Yin Z., Moriwaki H., Abe H., Miwa T., Han J., Soloshonok V. A., ChemistryOpen 2019, 8, 701–704; [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30c. Mei H., Yin Z., Miwa T., Moriwaki H., Abe H., Han J., Soloshonok V. A., Symmetry 2019. , 11, 578; [Google Scholar]
  • 30d. Mei H., Hiramatsu T., Takeda R., Moriwaki H., Abe H., Han J., Soloshonok V. A., Org. Process Res. Dev. 2019, 23, 629–634. [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

As a service to our authors and readers, this journal provides supporting information supplied by the authors. Such materials are peer reviewed and may be re‐organized for online delivery, but are not copy‐edited or typeset. Technical support issues arising from supporting information (other than missing files) should be addressed to the authors.

Supplementary


Articles from ChemistryOpen are provided here courtesy of Wiley

RESOURCES